Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Grant Support/Research Contract (Institutional) - Abbott Vascular; AstraZenca; Boston Scientific Corporation; Medtronic; Sanofi-Aventis; The Medicines Company; Bristol-Myers Squibb; Biotronik; Amgen; Idorsia; PhaseBio; Pfizer; Regeneron; Ironwood; Ischemix; Synaptic; Bayer AG; St. Jude Medical (now Abbott); Boehringer Ingelheim
• Equity/Stock(s)/Options (Personal) - Bristol-Myers Squibb